Shares of CARGO Therapeutics , Inc. (NASDAQ:CRGX) plummeted 75% following the company's decision to discontinue its Phase 2 ...

CARGO elects to discontinue FIRCE-1, a Phase 2 clinical study of firicabtagene autoleucel (firi-cel)1; Company believes results do not support a ...

Truist Securities revised its position on Cargo Therapeutics (NASDAQ:CRGX), currently trading at $13.19 with a market ...

CARGO Therapeutic announced that it has elected to discontinue FIRCE-1, a Phase 2 clinical study of firi-cel for patients with large B-cell lymphoma whose disease relapsed or was refractory to CD19 ...

Detailed price information for Cargo Therapeutics Inc (CRGX-Q) from The Globe and Mail including charting and trades.